TENX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TENX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tenax Therapeutics's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics's inventory stayed the same from Sep. 2023 to Dec. 2023 .
Tenax Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .
Tenax Therapeutics's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Tenax Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics Annual Data | |||||||||||||||||||||
Trend | Apr14 | Apr15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Tenax Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics (NAS:TENX) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Tenax Therapeutics's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Tenax Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tenax Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Tenax Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Robyn Hunter | director | 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
Eliot M Lurier | officer: Interim CFO | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Chrisopher Thomas Giordano | director, officer: CEO | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Armistice Capital, Llc | director | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital Master Fund Ltd. | director | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | director | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
June Sherie Almenoff | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
Michael H. Davidson | director | OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540 |
Declan Doogan | director | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Stuart Rich | officer: Chief Medical Officer | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Illya Keith Maher | director | C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022 |
Ronald R Blanck | director | 2001 WALNUT HILL LANE, IRVING TX 75038 |
Gerald T Proehl | director | |
James P. Mitchum | director | C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709 |
John P Kelley | officer: Chief Executive Officer | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
From GuruFocus
By Marketwired • 07-19-2023
By Business Wire Business Wire • 05-17-2021
By Business Wire Business Wire • 05-18-2022
By sperokesalga sperokesalga • 03-22-2023
By Business Wire Business Wire • 11-10-2020
By Stock market mentor Stock market mentor • 02-03-2023
By GuruFocusNews GuruFocusNews • 01-12-2022
By Business Wire Business Wire • 07-07-2021
By Business Wire Business Wire • 06-10-2021
By PRNewswire PRNewswire • 02-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.